ArticlePloS one2026
Endothelial activation and stress index in risk stratification and treatment optimization for critically ill patients with acute kidney injury: A retrospective cohort study from MIMIC-Ⅳ database.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndothelial dysfunction is critical in the pathogenesis of acute kidney injury (AKI). It sought to investigate the role of endothelial activation and stress index (EASIX) in risk stratification and treatment optimization for critically ill patients with AKI.
methodsUtilizing MIMIC-Ⅳ 3.1 database, a retrospective cohort study was undertaken. Given the non-normal distribution, EASIX was transformed logarithmically. The endpoints were 1-year and ICU all-cause mortality. The association was assessed using Kaplan-Meier curves, Cox models, restricted cubic splines and propensity score via overlap weights. Subgroup analyses were conducted to assess optimal population for EASIX application and to preliminarily explore its potential role in guiding treatment strategy optimization.
resultsIt comprised 17624 patients with AKI, exhibiting 1-year and ICU mortality rates of 44.6% and 19.2%. Elevated log2(EASIX) levels were independently associated with an increased 1-year mortality (HR: 1.41, 95% CI: 1.32-1.50) and ICU mortality (RR: 1.49, 95% CI: 1.38-1.62), as a finding corroborated by overlap-weighted propensity score analysis. Subgroup analyses indicated a stronger association in patients without severe AKI, CKD, sepsis or CRRT, and patients with lower levels of age or Acute Physiology Score (APS) Ⅲ and higher levels of albumin (p < 0.05 for all). The glucocorticoid use may be independently associated with an increased risk of 1-year (HR: 1.27, 95% CI: 1.21-1.34) and ICU (HR: 1.39, 95% CI: 1.31-1.47) mortality. The glucocorticoid-associated risk decreased as the log2(EASIX) level increased (p < 0.001).
conclusionIt found the positive association between log2(EASIX) levels and risk of mortality in critically ill patients suffering from AKI, particularly in those with decreased age or APS Ⅲ, elevated albumin, and those characterized by mild AKI, or absence of CKD, sepsis or CRRT. These findings underscored the significance of EASIX in enhancing risk stratification systems and in guiding personalized anti-inflammatory treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.